{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:12:26Z","timestamp":1791364346363,"version":"4.3.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-024-00684-8","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T18:07:30Z","timestamp":1732817250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-298X","authenticated-orcid":false,"given":"Viviane M.","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Rosenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Josleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Vantongeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Schmaljohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Facemire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1363-1077","authenticated-orcid":false,"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-1818","authenticated-orcid":false,"given":"Patrick","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-446X","authenticated-orcid":false,"given":"Jamie","family":"Lovaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-8227","authenticated-orcid":false,"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0671-2565","authenticated-orcid":false,"given":"Trevor R. F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"684_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"21","author":"RF Garry","year":"2023","unstructured":"Garry, R. F. Lassa fever\u2014the road ahead. Nat. Rev. Microbiol 21, 87\u201396 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"684_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02122438","volume":"175","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med. Microbiol. Immunol. 175, 153\u2013155 (1986).","journal-title":"Med. Microbiol. Immunol."},{"key":"684_CR3","first-page":"75","volume":"262","author":"JB McCormick","year":"2002","unstructured":"McCormick, J. B. & Fisher-Hoch, S. P. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75\u2013109 (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"684_CR4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.4269\/ajtmh.1974.23.1140","volume":"23","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Maher, M., Casals, J., Kissling, R. E. & Cacciapuoti, A. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am. J. Trop. Med. Hyg. 23, 1140\u20131149 (1974).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"684_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","volume":"327","author":"JK Richmond","year":"2003","unstructured":"Richmond, J. K. & Baglole, D. J. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327, 1271\u20131275 (2003).","journal-title":"BMJ"},{"key":"684_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/jama.1990.03450160063030","volume":"264","author":"D Cummins","year":"1990","unstructured":"Cummins, D. et al. Acute sensorineural deafness in Lassa fever. JAMA 264, 2093\u20132096 (1990).","journal-title":"JAMA"},{"key":"684_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3201\/eid1205.050052","volume":"12","author":"AM Macher","year":"2006","unstructured":"Macher, A. M. & Wolfe, M. S. Historical Lassa fever reports and 30-year clinical update. Emerg. Infect. Dis. 12, 835\u2013837 (2006).","journal-title":"Emerg. Infect. Dis."},{"key":"684_CR8","doi-asserted-by":"publisher","first-page":"e0006187","DOI":"10.1371\/journal.pntd.0006187","volume":"12","author":"EJ Mateer","year":"2018","unstructured":"Mateer, E. J., Huang, C., Shehu, N. Y. & Paessler, S. Lassa fever-induced sensorineural hearing loss: a neglected public health and social burden. PLoS Negl. Trop. Dis. 12, e0006187 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"684_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1752-1947-3-36","volume":"3","author":"PO Okokhere","year":"2009","unstructured":"Okokhere, P. O., Ibekwe, T. S. & Akpede, G. O. Sensorineural hearing loss in Lassa fever: two case reports. J. Med. Case Rep. 3, 36 (2009).","journal-title":"J. Med. Case Rep."},{"key":"684_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2020.08.021","volume":"100","author":"SC Ficenec","year":"2020","unstructured":"Ficenec, S. C. et al. Lassa fever induced hearing loss: the neglected disability of hemorrhagic fever. Int J. Infect. Dis. 100, 82\u201387 (2020).","journal-title":"Int J. Infect. Dis."},{"key":"684_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","volume":"18","author":"P Okokhere","year":"2018","unstructured":"Okokhere, P. et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect. Dis. 18, 684\u2013695 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"684_CR12","unstructured":"World Health Organization (2023). Disease Outbreak News; Lassa Fever\u2014Nigeria (2023)."},{"key":"684_CR13","unstructured":"Prevention, C.f.D.C.a. Lassa Fever (2022)."},{"key":"684_CR14","doi-asserted-by":"publisher","first-page":"e0005711","DOI":"10.1371\/journal.pntd.0005711","volume":"11","author":"OC Akhuemokhan","year":"2017","unstructured":"Akhuemokhan, O. C. et al. Prevalence of Lassa Virus Disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area. PLoS Negl. Trop. Dis. 11, e0005711 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"684_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14787210.2018.1512856","volume":"16","author":"GO Akpede","year":"2018","unstructured":"Akpede, G. O., Asogun, D. A., Okogbenin, S. A. & Okokhere, P. O. Lassa fever outbreaks in Nigeria. Expert Rev. AntiInfect. Ther. 16, 663\u2013666 (2018).","journal-title":"Expert Rev. AntiInfect. Ther."},{"key":"684_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","volume":"108","author":"MI Buba","year":"2018","unstructured":"Buba, M. I. et al. Mortality among confirmed Lassa fever cases during the 2015-2016 outbreak in Nigeria. Am. J. Public Health 108, 262\u2013264 (2018).","journal-title":"Am. J. Public Health"},{"key":"684_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/j.1365-3156.2012.03010.x","volume":"17","author":"DU Ehichioya","year":"2012","unstructured":"Ehichioya, D. U. et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005-2008. Trop. Med Int Health 17, 1001\u20131004 (2012).","journal-title":"Trop. Med Int Health"},{"key":"684_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002748","volume":"8","author":"JG Shaffer","year":"2014","unstructured":"Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PLoS Negl. Trop. Dis. 8, e2748 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"684_CR19","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3201\/eid1610.100774","volume":"16","author":"V Amorosa","year":"2010","unstructured":"Amorosa, V. et al. Imported Lassa fever, Pennsylvania, USA, 2010. Emerg. Infect. Dis. 16, 1598\u20131600 (2010).","journal-title":"Emerg. Infect. Dis."},{"key":"684_CR20","first-page":"193","volume":"15","author":"MS Mahdy","year":"1989","unstructured":"Mahdy, M. S. et al. Lassa fever: the first confirmed case imported into Canada. Can. Dis. Wkly Rep. 15, 193\u2013198 (1989).","journal-title":"Can. Dis. Wkly Rep."},{"key":"684_CR21","unstructured":"Lassa fever, imported case, Netherlands. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 75, 265 (2000)."},{"key":"684_CR22","unstructured":"Lassa fever imported to England. Communicable Disease Report 10, 99 (2000)."},{"key":"684_CR23","unstructured":"Lassa fever, case imported to Germany. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 75, 17\u201318 (2000)."},{"key":"684_CR24","unstructured":"Imported Lassa fever\u2014New Jersey, 2004. MMWR 53, 894-897 (2004)."},{"key":"684_CR25","doi-asserted-by":"publisher","first-page":"19145","DOI":"10.2807\/ese.14.10.19145-en","volume":"14","author":"S Atkin","year":"2009","unstructured":"Atkin, S. et al. The first case of Lassa fever was imported from Mali to the United Kingdom, February 2009. Eur. Surveill. 14, 19145 (2009).","journal-title":"Eur. Surveill."},{"key":"684_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3201\/eid2502.180836","volume":"25","author":"A Kofman","year":"2019","unstructured":"Kofman, A., Choi, M. J. & Rollin, P. E. Lassa Fever in Travelers from West Africa, 1969-2016. Emerg. Infect. Dis. 25, 245\u2013248 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"684_CR27","doi-asserted-by":"publisher","first-page":"taaa035","DOI":"10.1093\/jtm\/taaa035","volume":"27","author":"T Wolf","year":"2020","unstructured":"Wolf, T., Ellwanger, R., Goetsch, U., Wetzstein, N. & Gottschalk, R. Fifty years of imported Lassa fever: a systematic review of primary and secondary cases. J. Travel Med 27, taaa035 (2020).","journal-title":"J. Travel Med"},{"key":"684_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1179\/acb.2002.047","volume":"57","author":"R Colebunders","year":"2002","unstructured":"Colebunders, R., Van Esbroeck, M., Moreau, M. & Borchert, M. Imported viral haemorrhagic fever with a potential for person-to-person transmission: review and recommendations for initial management of a suspected case in Belgium. Acta Clin. Belgica 57, 233\u2013240 (2002).","journal-title":"Acta Clin. Belgica"},{"key":"684_CR29","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1080\/21645515.2017.1382780","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. DNA vaccines delivered by dermal electroporation elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs. Hum. Vaccines Immunother. 13, 3010\u20133019 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"684_CR30","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin Immunother. 13, 2902\u20132911 (2017).","journal-title":"Hum. Vaccin Immunother."},{"key":"684_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/vaccines1030262","volume":"1","author":"KA Cashman","year":"2013","unstructured":"Cashman, K. A. et al. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation. Vaccines1, 262\u2013277 (2013).","journal-title":"Vaccines"},{"key":"684_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.antiviral.2007.10.002","volume":"78","author":"BB Gowen","year":"2008","unstructured":"Gowen, B. B. & Holbrook, M. R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antivir. Res. 78, 79\u201390 (2008).","journal-title":"Antivir. Res."},{"key":"684_CR33","first-page":"523","volume":"52","author":"DH Walker","year":"1975","unstructured":"Walker, D. H., Wulff, H., Lange, J. V. & Murphy, F. A. Comparative pathology of Lassa virus infection in monkeys, guinea pigs, and Mastomys natalensis. Bull. World Health Organ. 52, 523\u2013534 (1975).","journal-title":"Bull. World Health Organ."},{"key":"684_CR34","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","volume":"15","author":"J Jiang","year":"2019","unstructured":"Jiang, J. et al. Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques. Hum. Vaccines Immunother. 15, 2066\u20132074 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"684_CR35","doi-asserted-by":"crossref","unstructured":"Mateo, M., et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl. Med. 13 eabf6348 (2021).","DOI":"10.1126\/scitranslmed.abf6348"},{"key":"684_CR36","unstructured":"Academies, N.R.C.o.t.N. Guide for the Care and Use of Laboratory Animals (The National Academies Press, 2011)."},{"key":"684_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jmv.1890220110","volume":"22","author":"O Tomori","year":"1987","unstructured":"Tomori, O., Johnson, K. M., Kiley, M. P. & Elliott, L. H. Standardization of a plaque assay for Lassa virus. J. Med. Virol. 22, 77\u201389 (1987).","journal-title":"J. Med. Virol."},{"key":"684_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1006\/viro.1998.9586","volume":"255","author":"JW Hooper","year":"1999","unstructured":"Hooper, J. W., Kamrud, K. I., Elgh, F., Custer, D. & Schmaljohn, C. S. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology 255, 269\u2013278 (1999).","journal-title":"Virology"},{"key":"684_CR39","doi-asserted-by":"publisher","first-page":"e01896","DOI":"10.1128\/mBio.01896-18","volume":"9","author":"KA Cashman","year":"2018","unstructured":"Cashman, K. A. et al. Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following Lassa virus exposure in Cynomolgus Macaques. mBio 9, e01896\u201318 (2018).","journal-title":"mBio"},{"key":"684_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-205","volume":"8","author":"LE Hensley","year":"2011","unstructured":"Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205 (2011).","journal-title":"Virol. J."},{"key":"684_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/vaccines6030050","volume":"6","author":"G Bowyer","year":"2018","unstructured":"Bowyer, G. et al. Activation-induced markers detect vaccine-specific CD4(+) T cell responses not measured by assays conventionally used in clinical trials. Vaccines 6, 50 (2018).","journal-title":"Vaccines"},{"key":"684_CR42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.0.CO;2-A","volume":"59","author":"IS Lukashevich","year":"1999","unstructured":"Lukashevich, I. S. et al. Lassa and Mopeia virus replication in human monocytes\/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J. Med. Virol. 59, 552\u2013560 (1999).","journal-title":"J. Med. Virol."},{"key":"684_CR43","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1086\/320722","volume":"183","author":"S Mahanty","year":"2001","unstructured":"Mahanty, S. et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 183, 1713\u20131721 (2001).","journal-title":"J. Infect. Dis."},{"key":"684_CR44","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1128\/JVI.01948-08","volume":"83","author":"S Baize","year":"2009","unstructured":"Baize, S. et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83, 5890\u20135903 (2009).","journal-title":"J. Virol."},{"key":"684_CR45","doi-asserted-by":"publisher","first-page":"e01367","DOI":"10.1128\/JVI.01367-20","volume":"94","author":"JR Port","year":"2020","unstructured":"Port, J. R. et al. Severe human Lassa fever is characterized by nonspecific T-cell activation and lymphocyte homing to inflamed tissues. J. Virol. 94, e01367\u201320 (2020).","journal-title":"J. Virol."},{"key":"684_CR46","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"684_CR47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or Mild COVID-19. Cell 183, 158\u2013168.e114 (2020).","journal-title":"Cell"},{"key":"684_CR48","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/infdis\/jix201","volume":"215","author":"AK McElroy","year":"2017","unstructured":"McElroy, A. K. et al. A case of human Lassa virus infection with robust acute T-cell activation and long-term virus-specific T-cell responses. J. Infect. Dis. 215, 1862\u20131872 (2017).","journal-title":"J. Infect. Dis."},{"key":"684_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41376-6","volume":"14","author":"AJ Ronk","year":"2023","unstructured":"Ronk, A. J. et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat. Commun. 14, 5603 (2023).","journal-title":"Nat. Commun."},{"key":"684_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).","journal-title":"Nat. Commun."},{"key":"684_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res 133, 218\u2013222 (2016).","journal-title":"Antivir. Res"},{"key":"684_CR52","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"684_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100690","volume":"4","author":"A Lemieux","year":"2024","unstructured":"Lemieux, A. et al. Enhanced detection of antigen-specific T cells by a multiplexed AIM assay. Cell Rep. Methods 4, 100690 (2024).","journal-title":"Cell Rep. Methods"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00684-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T19:04:53Z","timestamp":1732820693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00684-8","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.M.A., T.R.F.S., and L.M.H. are employees of Inovio Pharmaceuticals and as such receive salary and benefits, including ownership of stock and stock options from the company. J.J., J.B., A.P., S.R., and K.E.B. are former Inovio employees. All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}